STOCK TITAN

Vanguard Capital Management discloses 5,052,862 Rani Therapeutics (RANI) shares in ownership report

(Moderate)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Vanguard Capital Management reported its holdings of Rani Therapeutics Holdings Inc common stock, beneficially owning 5,052,862 shares, representing 4.49% of the class as of June 30, 2026. These securities have CUSIP 753018100.

Vanguard has sole voting power over 489,877 shares and sole dispositive power over 5,052,862 shares, with no shared voting or dispositive power. The holdings include securities managed by Vanguard Capital Management LLC and certain affiliated entities and business divisions, including Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC, and Vanguard Investments Australia Ltd.

The report notes that the position reflects securities held by Vanguard funds and client accounts over which these entities exercise voting and/or dispositive power. Interests of other persons in these securities are each below 5% of the class. The filing is signed by an authorized signatory, Head of Global Fund Administration, on July 31, 2026.

Positive

  • None.

Negative

  • None.
Beneficial ownership 5,052,862 shares Common stock of Rani Therapeutics beneficially owned by Vanguard Capital Management
Percent of class owned 4.49% Portion of Rani Therapeutics common stock class reported as beneficially owned
Sole voting power 489,877 shares Shares of Rani Therapeutics over which Vanguard has sole power to vote
Shared voting power 0 shares Shares of Rani Therapeutics over which Vanguard has shared voting power
Sole dispositive power 5,052,862 shares Shares of Rani Therapeutics over which Vanguard can solely direct disposition
Shared dispositive power 0 shares Shares of Rani Therapeutics with shared dispositive power reported
beneficially owned financial
"this reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
dispositive power financial
"over which Vanguard Capital Management LLC exercises dispositive power"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
sole voting power financial
"Sole Voting Power 489,877.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
percent of class financial
"Percent of class: 4.49 %"
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.
Investment Company Act of 1940 regulatory
"investment company registered under the Investment Company Act of 1940"
A U.S. federal law that sets the rulebook for pooled investment vehicles such as mutual funds, exchange-traded funds and similar money managers, requiring them to register with regulators, disclose holdings and fees, limit conflicts of interest, and follow governance standards. It matters to investors because these protections and transparency rules act like a referee and scoreboard, helping people compare funds, trust that managers follow fair practices, and spot hidden costs or risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What percentage of Rani Therapeutics (RANI) shares does Vanguard Capital Management report owning?

Vanguard Capital Management reports beneficial ownership of 4.49% of Rani Therapeutics common stock. This corresponds to 5,052,862 shares as of June 30, 2026, including holdings across certain Vanguard funds and managed accounts.

How many Rani Therapeutics (RANI) shares does Vanguard Capital Management have voting power over?

Vanguard Capital Management has sole voting power over 489,877 shares of Rani Therapeutics. It reports no shared voting power, while maintaining sole dispositive power over a larger number of shares.

What is the total number of Rani Therapeutics (RANI) shares Vanguard Capital Management can dispose of?

Vanguard Capital Management has sole dispositive power over 5,052,862 shares of Rani Therapeutics common stock. It reports zero shared dispositive power, meaning decisions to sell or otherwise dispose of these shares rest solely with Vanguard entities.

Which Vanguard entities are included in the Rani Therapeutics (RANI) ownership reported by Vanguard Capital Management?

The ownership reflects securities beneficially owned by Vanguard Capital Management LLC and affiliates, including Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC, and Vanguard Investments Australia Ltd, along with related funds and managed accounts.

Does any other single investor hold more than 5% of Rani Therapeutics (RANI) through Vanguard-managed accounts?

No. The disclosure states that no one other person's interest in the Rani Therapeutics securities reported by Vanguard Capital Management is more than 5% of the class, across investment companies and other managed accounts.

What type of Rani Therapeutics (RANI) security is covered and what is its CUSIP?

The position covers common stock of Rani Therapeutics Holdings Inc. The security is identified by CUSIP 753018100, which uniquely labels this class of equity for settlement and reporting purposes.





753018100

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd. This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power. This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release.


SCHEDULE 13G



Vanguard Capital Management
Signature:My Trieu-Gatt
Name/Title:Authorized Signatory, Head of Global Fund Administration
Date:07/31/2026